z-logo
open-access-imgOpen Access
Response of human normal and leukemia cells to factors released by amnion fragments in vitro
Author(s) -
Zofia Grzywocz,
Grażyna Hoser,
Stanisława Sabalińska,
Piotr Ładyżyński,
Jarosław Czubak,
Malgorzata Dworczynska,
Romuald Dębski,
Ewa PiusSadowska,
Bogdan Machalinski,
Jerzy Kawiak
Publication year - 2018
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0195035
Subject(s) - amnion , umbilical vein , jurkat cells , biology , fetal membrane , in vitro , cd31 , cell culture , microbiology and biotechnology , immunology , andrology , chemistry , placenta , fetus , medicine , biochemistry , t cell , immune system , pregnancy , genetics
Amnion is a membrane surrounding the embryo/fetus which determine growth factors and interleukins with angiogenic, immunogenic, and anti-inflammatory properties. The aim of the present study was to investigate the effects of conditioned culture medium from 24-h cultures of human amnion (hAM CCM) on migration and proliferation of human umbilical vein endothelial primary cells (HUVECs), freshly isolated bone marrow mononuclear cells (BM MNCs), and Jurkat leukemia cell line. Amnion membrane was freshly isolated from healthy placenta and its fragments cultured in vitro to produce hAM CCM. Members of the IGFBP protein family made up one third of all assayed proteins present in the hAM medium. The hAM CCM did not affect the proliferation rate of HUVECs or MNCs, but we observed more intensive migration of those cells, and lower expression of CD31 surface antigen on HUVECs as compared to control cultures. In contrast, Jurkat cells did not respond to hAM CCM treatment by proliferation or mobility change. The conditioned medium from 24-h cultures of human amnion is easy to obtain and is a convenient source of various growth and other factors that may be useful in practical medicine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here